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Synopsis
ATP-binding cassette transporter A7 (ABCA7) is highly expressed in the brain. Recent genome-wide association
studies (GWAS) have identified ABCA7 single nucleotide polymorphisms (SNPs) that increase Alzheimer’s disease
(AD) risk, however, the mechanisms by which ABCA7 may control AD risk remain to be fully elucidated. Based on
previous research suggesting that certain ABC transporters may play a role in the regulation of neurogenesis, we
conducted a study of cell proliferation and neurogenic potential using cellular bromodeoxyuridine (BrdU) incorporation
and doublecortin (DCX) immunostaining in adult Abca7 deficient mice and wild-type-like (WT) littermates. In the present
study counting of BrdU-positive and DCX-positive cells in an established adult neurogenesis site in the dentate gyrus
(DG) indicated there were no significant differences when WT and Abca7 deficient mice were compared. We also
measured the area occupied by immunohistochemical staining for BrdU and DCX in the DG and the subventricular
zone (SVZ) of the same mice and this confirmed that ABCA7 does not play a significant role in the regulation of cell
proliferation or neurogenesis in the adult mouse.
Key words: ABCA7, Alzheimer’s disease, bromodeoxyuridine, dentate gyrus, doublecortin, neurogenesis,
subventricular zone.
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INTRODUCTION
ATP-binding cassette transporter A7 (ABCA7) is a member of
the “A” subfamily of ATP-binding cassette transporters that were
initially characterized by their capacity to transport lipids and
other lipophilic molecules across membranes [1,2]. ABCA7 is
expressed in the brain where it appears to be predominantly loc-
alized in microglia and, to a lesser degree, in neurons and oli-
godendrocytes [3]. Several lines of evidence implicate a role for
ABCA7 in the regulation of Alzheimer’s disease (AD) risk and
amyloid pathology. Data from human genome-wide association
studies (GWAS) indicate ABCA7 is a risk factor for late-onset
AD [4–9]. Additional genetic studies confirm the important as-
sociation of ABCA7 single nucleotide polymorphisms (SNPs)
and methylation changes with AD [7–9], and recent work high-
lights that loss-of-function ABCA7 variants confer increased AD
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risk [10]. This is in agreement with data showing that the AD-
associated ABCA7 SNP (rs3764650 that does not result in an
amino acid change) is associated with reduced ABCA7 expres-
sion levels in AD cases [11].
In vitro studies revealed that ABCA7 transfection into cell
lines constitutively expressing human amyloid-β precursor pro-
tein (APP) results in a significant reduction in production of
amyloid-β peptide (Aβ) peptides [12], whereas siRNA-mediated
knockdown of ABCA7 increased Aβ production under similar
experimental conditions [13]. In addition, phagocytic clearance
of oligomeric Aβ was found to be impaired in ABCA7-deficient
macrophages compared with wild-type (WT) macrophages [14].
In general agreement with these cell culture studies, work in
AD mouse models has also provided evidence supporting a role
for ABCA7 in amyloid homoeostasis. In the J20 AD transgenic
mouse model, deletion of ABCA7 led to a doubling of insoluble
Aβ levels and amyloid plaques in mice assessed at 17 months
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of age [14]. An independent study using the same Abca7 null
(Abca7 − / − ) mouse line but crossed with the TgCRND8 AD
mouse model revealed an increase in the area of dense plaques
at 18 weeks of age that the authors concluded was likely to be a
reflection of the increased production of Aβ in the TgCRND8-
Abca7 − / − mice [13]. It should be noted that even in the absence
of the AD transgene expression, Abca7 − / − null mice were found
to exhibit an age-dependent increase in the levels of the patho-
genic (endogenous) Aβ42 peptide in the brain; assessed up to 6
months of age [13].
Although it is clear that ABCA7 has the capacity to regulate
amyloidogenesis in mice, an entirely different question that has
not been addressed centres on the potential impact that ABCA7
loss of function may have on adult neurogenesis. Our rationale
for asking this question is based on previous studies showing that
other ABC transporters including two that, like ABCA7, are also
from the “Class-A” subfamily (i.e. ABCA2, ABCA3) appear to
play a role in neurogenesis [15,16]. These studies along with the
extensive literature highlighting the importance of adult neuro-
genesis in AD (see [17–20], for recent comprehensive reviews of
this area) prompted our present study in which we have assessed
cellular proliferation and neurogenesis in the dentate gyrus (DG)




Abca7-deficient mice were generated and genotyped as described
previously [21]. All mice were on a C57BL/6j background and
backcrossed >15 times. Test mice were males at ∼8.5 months of
age (WT, n = 7, 251 +− 7 days old; Abca7 − / − , n = 7, 256 +− 9 days
old). The animals we refer to as “WT” control mice were litter-
mates derived from the same breeders that were used to gen-
erate the Abca7 − / − animals (i.e. both test cohorts were from
Abca7 + / − breeders). Animal ethics approval was from the Uni-
versity of Wollongong Animal Ethics Committee.
5-Bromo-2-deoxyuridine injection, tissue
preparation and immunohistochemistry
5-Bromo-2-deoxyuridine (BrdU, Sigma, B5002) was admin-
istered via intraperitoneal injection (i.p.) at a dose of 50 mg/kg
twice a day (8 a.m. and 8 p.m.) for three consecutive days prior to
euthanasia of animals. The animals were killed by methoxyflur-
ane inhalation 4 h after the final BrdU injection and perfused with
0.9 % NaCl followed by 4 % paraformaldehyde (PFA). Tissues
were preparation as described previously [22]. In brief, brains
were removed and post-fixed in phosphate-buffered 4 % PFA at
4 ◦C for 16 h then cryoprotected in 30 % (w/v) sucrose in 0.1 M
phosphate buffer for 48 h. One hemibrain was coronally sec-
tioned at 40 μm with a cryostat (CM1950, Leica Microsystems),
the sections were collected in six series and stored at − 20 ◦C in
cryoprotectant (3:3:4, glycerol:ethylene glycol:0.1 M phosphate
buffer, v/v/v) for histological or immunohistochemical analysis.
Every seventh hemibrain section was used for neurogenesis de-
tection as described previously [23,24]. Briefly, after cryoprotect-
ant removal, the sections were post-fixed with Bouin-4 [4 % (w/v)
PFA, 1 % (w/v) picric acid and 5 % (v/v) acetic acid, to improve
nuclear antigen unmasking] for 15 min, then processed in sodium
borohydride (0.1 mg/ml in 0.01 M PBS, to remove excess reactive
aldehyde groups), denaturation (2 M HCl, 22 ◦C, 1 h, then neut-
ralization with 0.1 M borate buffer, pH 8.5) and H2O2 quench-
ing [1 % (v/v) H2O2 in PBS, 22 ◦C, 30 min to quench endogen-
ous peroxidase activity]. After blocking in Vector MOM reagent
(Vector), the sections were stained with rat monoclonal anti-BrdU
(0.5 μg/ml; Abcam, AB6326, from Sapphire Bioscience Pty Ltd)
and biotinylated with goat-anti-rat IgG (1:200, Vector Laborator-
ies), followed by Vectastain Elite ABC reagent (Vector Laborat-
ories) or Streptavidin-HRP (Sigma, S2438 1:2000) and staining
was visualized with ImmPact diaminobenzidine (DAB) peroxi-
dase substrate (Vector Laboratories). To confirm the specificity of
primary antibodies, control experiments were performed where
sections were incubated for 16 h in the absence of primary anti-
body. Doublecortin (DCX), a commonly used marker for neur-
oblast cells [25,26] in the adult brain, was detected using rabbit
anti-DCX (1:2000, Abcam, Ab18723, from Sapphire Bioscience
Pty Ltd) as described as above for the BrdU protocol except
the denaturation and MOM blocking steps were omitted and the
secondary antibody used was biotinylated goat-anti-rabbit IgG
(Sigma, B7389, 1:2000). All the staining procedures were car-
ried out within a single immunostaining session to minimize
variability.
Image acquisition and quantification
Immunohistochemically stained sections were captured using
a Scanscope XT Image scanner at 20× (Scanscope Console
V10.2.0352, Aperio Digital Pathology System, Aperio Technolo-
gies). The images were exported in tiff format from Imagescope
software (Aperio Technologies), and analysed using ImageJ soft-
ware (http://rsbweb.nih.gov/ij/) using an established quantitative
method [27]. Representative images were assembled with Pho-
toshop CS2 for presentation in the figures. The numbers of BrdU
+ ve and DCX + ve cells in the DG were directly counted in the
immunostained sections (every seventh coronal section, five sec-
tions per mouse) in a blinded manner under 20× magnification.
This was achieved using tiff files generated from the Scanscope
XT Image scanned images and the data were expressed as pos-
itive cell number per mm2. Due to the clustering of BrdU + ve
cells in the SVZ and the overlap of neuronal structures in SVZ
DCX staining, it was impractical to count absolute cell numbers
and therefore the data were only acquired as positive stained oc-
cupied area (μm2) for this region of interest in each section (as
described below).
To quantify BrdU + ve and DCX + ve staining, five coronal
sections per brain were collected, 240 μm apart, grossly corres-
ponding to sections 1.2–0.0 mm anterior to the Bregma ( + 1.2–
0.0) according to the mouse brain atlas [28], were selected to
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measure the area occupied by positive staining in a defined re-
gion of interest area of the SVZ, i.e., the entire lateral wall of
SVZ from corpus callosum to the anterior commissure (selec-
ted area: approximately 0.8–1.2 mm2, mean +− S.E.M., 0.94 +−
0.07 mm2); and for measurement of hippocampal neurogenesis,
five coronal sections spanning from 1.7 to 2.7 mm posterior to the
Bregma ( − 1.7 to − 2.7) were chosen to analyse the area occu-
pied by positive staining in the known neurogenic region, i.e. the
DG. This region includes the molecular layer, outer granule cell
layer, subgranular zone (the most neurogenic region of the hippo-
campus) and hilus in the hippocampus formation (selected area
approximately 0.8–1.2 mm2, mean +− S.E.M.: 0.93 +− 0.11 mm2).
Statistical analysis
Quantitative data are presented as mean +− S.E.M. (represented
by the error bars). Statistical differences were assessed using the
Student’s t test where P < 0.05 was considered significant.
RESULTS AND DISCUSSION
BrdU staining was used to assess cell proliferation in the DG of
both WT and Abca7 − / − mice, whereas DCX staining was used
as a marker of neurogenesis. Consistent with previous studies, we
detected strong BrdU and DCX staining in the hippocampus (Fig-
ure 1). The immunohistochemical labelling was detected mainly
in the subgranular zone of the DG. Evidence for neurogenesis
was also clearly detected in the SVZ (Figure 2). Active cellular
proliferation in the SVZ was detected by BrdU cluster-like stain-
ing within the wall of lateral ventricle (Figure 2E). Fine neuronal
processes with bifurcations were evident in the SVZ when DCX
immunostaining was applied (Figure 2F). We did not observe any
gross (qualitative) differences to overall structure of proliferat-
ing cells when WT and Abca7 − / − mice were compared. Direct
counting of BrdU + ve cells and DCX + ve cells in the DG
indicated that Abca7 − / − loss did not significantly affect neuro-
genesis is this location (Figure 3). Furthermore, a quantitative
evaluation of BrdU and DCX staining area in the DG and SVZ
indicated there were no significant differences in neurogenesis
comparing WT and Abca7 − / − mice (Figure 4).
Although we cannot rule out the possibility that glial progen-
itors are affected by Abca7 loss, this seems unlikely given the
lack of significant change in BrdU incorporation in both the DG
and SVZ. Also, our findings do not preclude the possibility that
ABCA7 contributes to embryonic neurogenesis as this has not
been assessed in the present study.
There is mounting evidence that ABCA7 plays a role in regu-
lating the pathways leading to AD [29]. Studies in cell lines and
mouse models suggest that a loss of ABCA7 function may have
deleterious consequences for Aβ homoeostasis in the brain [12–
14]. This is consistent with the previously reported significant
association of ABCA7 SNPs with amyloid plaque load in human
subjects [6]. Indeed, recent genetics studies have shown that loss-
of-function ABCA7 variants confer increased AD risk [10]. Even
Figure 1 Representative coronal sections immunostained for
BrdU and DCX quantification in the DG
Low-magnification images (selected from − 1.8 to − 2.2 mm posterior
to Bregma from an 8-month-old male WT mouse) demonstrate the dis-
tribution of BrdU (A) and DCX (D) immunoreactivity in a representative
coronal sections. As predicted, the majority of BrdU + ve and DCX + ve
cells were located in the hippocampus. Panels “B” and “E” are enlarged
photomicrographs of the boxed areas from panels “A” (BrdU) and “D”
(DCX) respectively. Panels “C” and “F” are high-power images illustrat-
ing BrdU and DCX DG staining patterns in more detail. The broken-line
arrows point to the corresponding zoomed pictures. Scale bar: for A
and D is 500 μm; for B and E is 150 μm; for C and F is 25 μm).
though the available evidence points towards a role for ABCA7
regulating Aβ homoeostasis, the true function of ABCA7 in
the brain is still an open question. It is therefore important to
investigate additional pathways that may be influenced by
ABCA7 in order to understand its true function(s) in the AD
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
c© 2016 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution Licence 3.0. 3
H. Li, T. Karl and B. Garner
Figure 2 Representative coronal sections immunostained for
BrdU and DCX quantification in the SVZ
Low-magnification images [selected from + 1.1 mm anterior to Bregma
from an 8-month-old male Abca7− / − mouse (A–C) and an 8-month-old
male WT mouse (D–F)] demonstrate the distribution of BrdU (A) and
DCX (D) immunoreactivity in representative coronal sections. Proliferat-
ing BrdU + ve cells were clearly detected within the wall of the lateral
ventricle as illustrated in “A”, and viewed at higher magnifications (ro-
tated 90◦ clockwise) in “B” and “C”. DCX staining of neuroblasts in a
coronal section of the SVZ is presented in panels “D”–“F”. Fine pro-
cesses with bifurcations were detected as DCX + ve immunostaining
(in panel F) in the SVZ. Similar neuroblast morphology was seen in the
DG (i.e. compare figure F with Figure 1F). The broken-line arrows point to
the corresponding zoomed pictures. Scale bar: for A and D is 500 μm;
for B and E is 150 μm; for C and F is 25 μm).
context. An additional rationale for the present study is the liter-
ature suggesting certain ABC transporters play a role in the regu-
lation of neurogenesis. In this context, ABCA2, ABCA3, ABCB1
and ABCG2 have been suggested to play a role in neurogenesis
Figure 3 Cell counting in the DG confirms that deletion of Abca7
does not have a significant impact on adult neurogenesis
Histograms illustrate the quantitative evaluation of BrdU + ve cells
and DCX + ve cells in the DG from WT and Abca7− / − (A7− / − ) mice.
Measurement of the BrdU + ve and DCX + ve immunoreactive cell
number was undertaken on five sections for in each mouse as described
in the “Materials and Methods” section. The number of mice analysed
was WT (n = 7) and A7− / − (n = 7). There were no statistical differences
in the number of either BrdU + ve or DCX + ve cells present in the DG
when WT and Abca7− / − animals were compared. Data (mean +− S.E.M.)
in histograms represent the number of cells detected/mm2. Note: due
to the overlapping clusters of cells present in the SVZ (see Figure 2)
and the difficulty in unambiguously identifying single cells, cell numbers
were not quantified for this region.
[15]. Furthermore, ABCA2 is a marker of neural progenitors in
the adult mouse brain [16]. Despite the structural similarities
of ABCA7 with these proteins, and the fact that ABCA7 is ex-
pressed at a relatively high level in the brain [2], the results from
our current study suggest that ABCA7 does not play a major role
in the regulation of cell proliferation or neurogenesis in the DG
or SVZ of adult mice.
It is also worth considering how loss of ABCA7 function may
impact adult neurogenesis in the AD setting. Although the roles
that APP proteolytic fragments may play in regulating neuro-
genesis are far from clear [17–20,30,31], there is evidence that
Aβ42 may inhibit adult neurogenesis [32–34]. Indeed, as previ-
ously suggested [17], the majority of AD mouse models that are
based on APP mutations exhibit reduced neurogenesis. It might
therefore be predicted that in an environment where ABCA7 is
required to remove a toxic insult (e.g. phagocytic clearance of Aβ
peptides that would otherwise inhibit neurogenesis), an indirect
effect due to the loss of ABCA7 function may become apparent.
These types of hypotheses are difficult to test experimentally as
it would be hard to separate the effects of the toxic insult from
ABCA7 function per se. Nonetheless, it remains possible that
ABCA7 may have an impact on neurogenesis under certain condi-
tions that were not modelled in our current assessment. Based on
our current data, however, it is reasonable to assume that ABCA7
is unlikely to play a major direct role in adult neurogenesis
in humans. In conclusion, our current BrdU incorporation and
DCX labelling experiments indicate that deletion of Abca7 does
not have a significant impact on adult neurogenesis in mice.
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Figure 4 Deletion of Abca7 does not have a significant impact on
adult neurogenesis
Histograms illustrate the quantitative evaluation of BrdU and DCX in the
DG (A) and SVZ (B) from WT and Abca7− / − (A7− / − ) mice. Measure-
ment of the positive BrdU and DCX immunoreactive area in specified
regions of interest of both the DG and SVZ was undertaken on five
sections for each region in each mouse as described in the “Materials
and Methods” section. The staining analysis was quantified by ImageJ
software. The number of mice analysed was WT (n = 7) and A7− / −
(n = 7). There were no statistical differences in the area (μm2/section)
for BrdU or DCX immunoreactivity in either the DG or SVZ when WT
and Abca7− / − animals were compared. Data (mean +− S.E.M.) in histo-
grams represent the relative value as normalized with to WT (arbitrarily
set at 1.0).
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